 Enzymotec
Ltd. is a biotech company focused on the research, development, and
production of bio-active lipid-based compounds and nutritional
ingredients. The company has three business segments: Nutrition,
Pharma, and VAYA Pharma.
The Nutrition segment develops and
markets lipid-based nutritional ingredients and medical foods that
address a range of health conditions, including cognitive,
cardiovascular, and metabolic health. The Pharma segment is focused on
developing drugs for the treatment of neurodegenerative and metabolic
diseases. The VAYA Pharma segment is engaged in the development,
manufacture, and marketing of products based on lipid-based compounds
that have therapeutic benefits.
Enzymotec was founded in 1998
and is headquartered in Israel. The company's products are sold
worldwide through a network of distributors and strategic partners.
In 2018, Enzymotec was acquired by Frutarom, a flavor and
fragrance company, for $290 million. Since then, Enzymotec has
operated as a subsidiary of Frutarom.
Enzymotec's products have
received a number of awards and recognitions. For example, its Sharp
PS Gold product, which is used in dietary supplements for cognitive
health, won the NutrAward for Best New Ingredient at the 2012 Natural
Products Expo West.
The company has also been recognized for
its sustainability efforts. In 2016, Enzymotec was included in the
FTSE4Good Index, which is a global index of companies that meet
environmental, social, and governance criteria.
|
